Suppr超能文献

9L大鼠脑肿瘤多细胞球体对单次和分次剂量1,3-双(2-氯乙基)-1-亚硝基脲的反应

Response of 9L rat brain tumor multicellular spheroids to single and fractionated doses of 1,3-bis(2-chloroethyl)-1-nitrosourea.

作者信息

Sano Y, Hoshino T, Barker M, Deen D F

出版信息

Cancer Res. 1984 Feb;44(2):571-6.

PMID:6692362
Abstract

This study was designed to examine the relative effect of each of four fractions of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) against 9L rat brain tumor multicellular spheroids and to compare the results of the cell survival and growth delay assays. Similar levels of cell kill resulted when BCNU was administered either as single fractions of 1.5, 3.0, 4.5, or 6.0 micrograms/ml for 1 hr or as one to four fractions of 1.5 micrograms/ml that were administered sequentially for 1 hr each. Survival was increased if the assay was delayed until 24 hr after drug treatment, which indicates that 9L cells in spheroids recover from BCNU-induced potentially lethal damage. When BCNU was administered in 1.5-micrograms/ml fractions, plating efficiencies depended markedly on the interval between the fractions. The 12-hr protocol produced an overall higher cell kill. Fractionation schedules of 24 and 36 hr produced less cell kill than did the other schedules. Survival plateaued for the last three treatments with BCNU in the 36-hr schedule. Cells in S phase at the time of administration of the initial 1.5-micrograms/ml fraction of BCNU moved into G1- and G2-M phases by 12 hr after treatment. For time periods longer than 12 hr, cells began to appear in the BCNU-resistant S phase. Thus, the movement of cells into the drug-sensitive and -resistant phases after the first fraction correlates well with the corresponding overall cytotoxic effect produced by treatment with the combined BCNU (1.5 micrograms/ml) fractions. For a higher concentration (3.0 micrograms/ml for 1 hr), maximum cell kill was reached within the 12- to 18-hr interval, after which cell kill plateaued. Cells were not found in the S-phase fraction 12 to 36 hr after the first treatment with 3.0 micrograms/ml; maximum cell kill for the fractionated protocols resulted at these times. Therefore, BCNU, which is classified as a cell cycle-nonspecific drug, can induce a partial synchrony in 9L spheroid cells, which determines the overall cytotoxicity produced by fractionated BCNU protocols. Although spheroids did not shrink during or after exposure to BCNU, growth was retarded by treatment with all doses and schedules. An optimum time point for growth delay measurement could not be determined from the data. However, correlations between cell survival and growth delay were obtained with arbitrarily chosen end point volumes of four and ten times the volume at the time of treatment.

摘要

本研究旨在检测1,3-双(2-氯乙基)-1-亚硝基脲(BCNU)的四个组分各自对9L大鼠脑肿瘤多细胞球体的相对效应,并比较细胞存活和生长延迟试验的结果。当BCNU以1.5、3.0、4.5或6.0微克/毫升的单一组分给药1小时,或按1.5微克/毫升的一至四个组分依次给药、每次给药1小时时,产生的细胞杀伤水平相似。如果试验延迟至药物治疗后24小时进行,则存活率会增加,这表明球体中的9L细胞可从BCNU诱导的潜在致死性损伤中恢复。当以1.5微克/毫升的组分给药BCNU时,接种效率明显取决于各组分之间的间隔时间。12小时方案产生的总体细胞杀伤率更高。24小时和36小时的分割方案产生的细胞杀伤比其他方案少。在36小时方案中,BCNU的最后三次治疗的存活率趋于平稳。在最初给予1.5微克/毫升BCNU组分时处于S期的细胞,在治疗后12小时进入G1期和G2-M期。对于超过12小时的时间段,细胞开始出现在对BCNU耐药的S期。因此,细胞在第一次给药后进入药物敏感和耐药期的情况与联合使用BCNU(1.5微克/毫升)组分治疗所产生的相应总体细胞毒性效应密切相关。对于更高浓度(3.0微克/毫升,1小时),在12至18小时的间隔内达到最大细胞杀伤,此后细胞杀伤趋于平稳。在第一次用3.0微克/毫升治疗后12至36小时,未在S期组分中发现细胞;分割方案的最大细胞杀伤在这些时间出现。因此,被归类为细胞周期非特异性药物的BCNU可在9L球体细胞中诱导部分同步化,这决定了分割BCNU方案产生的总体细胞毒性。尽管球体在暴露于BCNU期间或之后没有缩小,但所有剂量和方案的治疗均会抑制其生长。无法从数据中确定生长延迟测量的最佳时间点。然而,通过任意选择治疗时体积的四倍和十倍的终点体积,获得了细胞存活与生长延迟之间的相关性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验